298 results about "Urea derivatives" patented technology

The present invention relates to compositions which contain at least one epoxide adduct A having on average more than one epoxide group per molecule, at least one polymer B of the formula (I), at least one thixotropic agent C, based on a urea derivative in a nondiffusing carrier material, and at least one curing agent D for epoxy resins, which is activated by elevated temperature. This composition serves in particular as an adhesive and has an extremely high dynamic resistance to cleavage, in particular at low temperatures. The invention furthermore relates to impact strength modifiers terminated with epoxide groups and of the formula (I). It has been found that these novel impact strength modifiers result in a significant increase in impact strength in epoxy resin compositions, in particular in two-component epoxy resin compositions.

This invention relates to novel diaryl ureas, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with cytotoxic therapies.

There are presented compounds of the formulaor a pharmaceutically acceptable salt thereof, which are active adenosine A2B receptor antagonists and useful in the treatment of diabetes, diabetic retinopathy, asthma and diarrhea.

The present invention relates to certain pyrazole derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the prophylaxis or treatment of progressive multifocal leukoencephalopathy.

Compounds of formula (I): wherein: R1 is alkyl; R2a, R2b, R2c and R2d are the same or different and each is hydrogen, optionally substituted alkyl or various other organic groups; R3 is alkyl; R4 is a group of formula (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX): wherein: A1 is a single bond, alkylene or alkenylene; A2 is or alkenylene; A3 is a single bond, alkyleneor alkenylene; R5a and R5b are the same or different and each is hydrogen, alkyl or various other groups; R6 is alkyl or phenyl; R7 is hydrogen or alkyl; R8 is alkyl or various other groups; and n is 0 and pharmaceutically acceptable salts thereof have valuable inhibitory activity against acyl-CoA: cholesterol acyl transferase.

Substituted amide and urea derivatives useful as inhibitors of Rho kinase are described, which inhibitors can be useful in the treatment of various disorders such as cardiovascular diseases, cancer, neurological diseases, renal diseases, bronchial asthma, erectile dysfunction and glaucoma.

The present invention relates to compounds of formula (I), pharmaceutical compositions which contain them and methods for treating cancer using compounds of formula (I).

The invention belongs to the technical field of nanometer material preparation, and relates to a method for loading nanocrystalline metal oxide or nanocrystalline metal materials by porous carbon. Urea derivatives, saccharides and metal salt can form the characteristics of even mixed solutions at certain temperature, the porous carbon is formed in situ after dehydration and carbonization, and then the nanocrystalline metal oxide or the nanocrystalline metal materials loaded by the porous carbon are prepared through high temperature treatment. According to the method, the raw material ratio, response time, heat treatment temperature and other synthesis condition are changed, and carrying type nanometer materials with the carrying amount, the size of the particle diameter, the crystalline phase and components simultaneously controllable can be obtained. The whole process has the advantages of being easy to operate, environmentally friendly, low in cost and the like, the obtained nanocrystalline metal oxide or nanocrystalline metal materials loaded by the porous carbon have wide application prospects in industrial catalysis, water treatment, electrochemistry and other aspects.

The invention provides methods and compositions for treating conditions mediated by various kinases wherein derivatives of urea compounds are employed. The invention also provides methods of using the compounds and / or compositions in the treatment of a variety of diseases and unwanted conditions in subjects.

The invention relates to a novel preparation method of 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidyl-4-yl)urea hemitartrate (pimavanserin tartrate), particularly a pharmaceutical compound for treating Parkinson's disease, of which the structural formula is disclosed as Formula (I). The invention also relates to a novel intermediate of the preparation method.

The invention relates to a vaccine composition comprising:a) inactivated whole virus, andb) a stabilizing excipient which comprises:i. a buffer solution,ii. a mixture of essential and nonessential amino acids,iii. a disaccharide,iv. a polyol,v. a chelating agent,vi. urea or a urea derivative, andvii. a nonionic surfactant.

Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.

The invention provides methods and compositions for treating conditions mediated by Bcr-Abl. The invention also provides methods of using the compounds and / or compositions in the treatment of a variety of diseases and unwanted conditions in subjects.

The present invention is related to a compound of formula (I)wherein R1a, R1b, R1c, R1d, R2a, R2b, R3, R4, p, r and are as defined herein, its preparation, pharmaceutical composition and use as a modulator of the activity of the 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1).

The present invention relates to compounds of formula (I), pharmaceutical compositions which contain them and methods for treating cancer using compounds of formula (I).

The present invention provides a urea derivative or a salt thereof, which is useful as a therapeutic agent for thrombosis. The derivative is represented by Formula (I): wherein Cy is an aromatic hydrocarbon group which may be substituted or an aromatic heterocyclic group which may be substituted; R1 is a hydrogen atom or a hydrocarbon group which may be substituted; V is —C(O)—, —S(O)—, or —S(O)2—; W is —N(R2)—, —O—, or a bond (wherein R2 is a hydrogen atom or a hydrocarbon group which may be substituted); X is alkylene which may be substituted; Y is —C(O)—, —S(O)—, or —S(O)2—; Z is a bond, a chain hydrocarbon group which may be substituted, or —N═; ring A is a non-aromatic nitrogen-containing heterocyclic ring which may be substituted; ring B is a nitrogen-containing heterocyclic ring which may be substituted; and [Chemical formula 2], are each independently a single bond or a double bond; provided that R1 may be bonded to R2 to form a non-aromatic nitrogen-containing heterocyclic ring and that R2 may be bonded to a substituent of X to form a non-aromatic nitrogen-containing heterocyclic ring which may be substituted.

A biodegradable polymer includes a) 20 to 60% of a mixture of starch and / or a modified starch, b) 8 to 22% of starch plasticisers and processing agents c) 30 to 70% of one or more biodegradable aliphatic polyesters d) 1 to 10% of a layered silicate clay mineral. The silicate mineral is an organoclay which has been formed by reacting clay with an intercalating chemical to compatibilise it with the polymers so that the clay is exfoliated and makes the blend amorphous. The polymers may also include the usual additives including e) from 0 to 20% by weight of a polyol plasticiser f) from 0.1 to 1.5% by weight of a C12–22 fatty acid or salt or a destructing agent preferably urea and / or urea derivatives, and g) from 0 to 12% by weight of added water. The polyester may be modified by reaction with maleic anhydride.

A biodegradable polymer includes a) 20 to 60% of a mixture of starch and / or a modified starch, b) 8 to 22% of starch plasticisers and processing agents c) 30 to 70% of one or more biodegradable aliphatic polyesters d) 1 to 10% of a layered silicate clay mineral. The silicate mineral is an organoclay which has been formed by reacting clay with an intercalating chemical to compatibilise it with the polymers so that the clay is exfoliated and makes the blend amorphous. The polymers may also include the usual additives including e) from 0 to 20% by weight of a polyol plasticiser f) from 0.1 to 1.5% by weight of a C12-22 fatty acid or salt or a destructing agent preferably urea and / or urea derivatives, and g) from 0 to 12% by weight of added water. The polyester may be modified by reaction with maleic anhydride.

Methods and preparations for treating disorders of the eye and / or causing posterior vitreous disconnection or disinsertion. Preparations containing a) urea, b) urea derivatives (e.g., hydroxyurea, thiourea), c) a non-steroidal anti-inflamatory agents, d) antmetabolites, e) urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e.g., adenine, adenosine, cytosine, cytadine, guanine, guanitadine, guanidinium, thymidine, thimitadine, uradine, uracil, cystine), uric acid, calcium acetal salicylate, ammonium sulfate or other compound capable of causing non-enzymatic dissolution of the hyaloid membrane or e) any of the possible combinations thereof, are administered to the eye in therapeutically effective amounts.

Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, are useful in the treatment of systolic heart failure including congestive heart failure.

The present invention relates to a composition comprising: (i) an anti-microbial agent comprising a polymeric biguanide, alone or in combination with at least one other microbiologically active component selected from the group consisting of quaternary ammonium compounds, monoquaternary heterocyclic amine salts, urea derivatives, amino compounds, imidazole derivatives, nitrile compounds, tin compounds or complexes, isothiazolin-3-ones, thiazole derivatives, nitro compounds, iodine compounds, aldehyde release agents, thiones, triazine derivatives, oxazolidine and derivatives thereof, furan and derivatives thereof, carboxylic acids and the salts and esters thereof, phenol and derivatives thereof, sulphone derivatives, imides, thioamides, 2-mercapto-pyridine-N-oxide, azole fungicides, strobilurins, amides, carbamates, pyridine derivatives, compounds with active halogen groups, and organometallic compounds; and (ii) an amphoteric co-polymer of the Formula (1): wherein:[A] is of Formula (9), [B] is of Formula (10), [C] is of Formula (12), [D] is of Formula (13), and X is of Formula (11), wherein [A], [B], [C] and [D] may occur in any order; T is an optionally substituted substituent; L, G and Z each independently is an optionally substituted linking group; R1, R2 and R3 are each independently H, optionally substituted C1-20-alkyl or optionally substituted C3-20-cycloalkyl; R4 and R5 are each independently H or C1-4-alkyl; q is 15 to 1000; p is 3 to 50; J is an optionally substituted hydrocarbyl group; F is an acidic substituent; E is a basic substituent; m is 0 to 350; n is 1 to 75; v is 0 to 100; y is 1 to 100; b is 0, 1 or 2; s is 0 or 1; w is 1 to 4; and provided that at least one of R4 and R5 is H.

This invention relates to tetrahydro-naphthalene and urea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The tetrahydro-naphthalene and urea derivatives of the present invention have vanilloid receptor (VR1) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urological diseases or disorders, such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor overactivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, and inflammatory disorders such as asthma and chronic obstructive pulmonary (or airways) disease (COPD).

The present invention relates to an aqueous cleaning composition used to remove unwanted organic and inorganic residues and contaminants from semiconductor substrates. The cleaning composition comprises a urea derivative such as, for example, dimethyl urea, as the component that is principally responsible for removing organic residues from the substrate. A fluoride ion source is also included in the cleaning compositions of the present invention and is principally responsible for removing inorganic residues from the substrate. The cleaning compositions of the present invention have a low toxicity and are environmentally acceptable.

Benzoyl urea derivatives that are alpha helical peptides mimetics that mimic BH3-only proteins, compositions containing them, their conjugation to cell-targeting-moieties, and their use in the regulation of cell death are disclosed. The benzoyl urea derivatives are capable of binding to and neutralizing pro-survival Bcl-2 proteins. Use of benzoyl urea derivatives in the treatment and / or prophylaxis of diseases or conditions associated with deregulation of cell death are also described.

The present invention relates to a water dispersible polyisocyanate composition bearing urea comprising (a) an aliphatic polyisocyanate or a mixture of aliphatic polyisocyanates or a mixture of aliphatic polyisocyanates with other polyisocyanates; and (b) a reaction product of component (a) with component (c) a polyether amine or a mixture of a polyether amine and a polyether alcohol. The present invention also relates to a water dispersible polyisocyanate composition bearing urea and urea derivatives which is obtained by heating the above composition bearing urea for conducting a subsequent reaction, to increase the numbers of isocyanate functional groups contained in said composition, wherein the urea derivatives include biuret, triuret and tetrauret, and most of them are biuret. The present invention further relates to a water dispersible polyisocyanate composition bearing biuret which is obtained by heating the above composition bearing urea for conducting a subsequent reaction, to increase the numbers of isocyanate functional groups contained in said composition. The present invention another relates to an aqueous resin adhesive which contains the water dispersible polyisocyanate composition of the present invention and an aqueous resin containing active hydrogen reactive groups.

Compositions suitable for use as wood adhesives are described, which compositions comprise: (a) a polymeric component selected from the group consisting of lignins, proteins, and mixtures thereof, (b) an adhesion promoter comprising at least one component selected from the group consisting of (i) adducts of an epoxide and a resin selected from the group consisting of polyamine resins, polyamidoamine resins, polyamide resins, and combinations thereof, and (ii) combinations of a curing agent and a compound having at least one amine, amide, imine, imide, or nitrogen-containing heterocyclic functional group capable of reacting with at least one functional group of the polymeric component; and (c) an additive selected from the group consisting of urea, N-substituted ureas, N,N-disubstituted ureas, N,N′-disubstituted ureas, N,N,N′-trisubstituted ureas, N,N,N′,N′-tetrasubstituted ureas, urea derivatives, and mixtures thereof.

A medicament which contains a urea derivative or a salt thereof as an active ingredient is disclosed. The medicament has an excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, incontinence and / or inflammatory disorders.